GC Wellbeing, a subsidiary of GC, has released the results of a study regarding its placenta injection Laennec’s regenerative effects.
The treatment has won the regulatory approval to improve liver function in patients with chronic liver disease. Human body hydrolysate, its main ingredient, is effective in improving fatigue.
The drug is the only treatment that passed safety and efficacy during the re-evaluation of human body hydrolyzate in 2010.
In the study, the company confirmed the effects of Laennec’s liver regeneration in various fields. As a result, Laennec administration group’s hepatocyte growth factor significantly increased compared to the control group in a liver-resected animal model.
The liver regeneration rate after three days was also 22 percent higher in the treatment group than in the control group, and the company confirmed that the treatment activates cytokine, a substance that helps the liver regeneration.
“The results of this study confirm Laennec's potential to help patients with hepatic resection,” Professor Cho Jae-won of the department of transplantation surgery at Samsung Medical Center. “We plan to continue research on whether Laennec can be used in other related diseases.”
International Journal of Molecular Medicine published the results of the study.